GlassScriptPhysician profile
James E Froelich
NPI 1649264656
$6,922.71
in general payments reported to CMS, 2019-2025
21 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $554 · 2021: $1,261 · 2022: $723 · 2023: $832 · 2024: $752 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,339.04 | 2019-2024 | Otezla |
| Abbott Laboratories | $870.63 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $721.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $562.30 | 2019-2021 | |
| Novo Nordisk INC | $491.53 | 2019-2023 | |
| Glaxosmithkline, LLC. | $417.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $383.95 | 2025 | Auvelity |
| Lilly USA, LLC | $276.86 | 2019-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $273.66 | 2019 | |
| Allergan, INC. | $261.22 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.44 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $218.95 | 2022-2024 | Quviviq |
| Pfizer INC. | $125.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.94 | 2023 | |
| Optinose US, INC. | $117.60 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $112.62 | 2020 | |
| Microport Orthopedics INC | $105.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.30 | 2019 | |
| Merck Sharp & Dohme LLC | $89.48 | 2019 | |
| Medtronic, INC. | $77.43 | 2021 | |
| Dexcom, INC. | $15.24 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Froelich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.